

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**In the claims:**

Please cancel claims 20-28 and 32-34 without prejudice.

Claims 1-28 (Canceled)

Claim 29 (Previously presented)

A method of differentiating a premature natural killer cell into a mature natural killer cell, comprising treating to premature natural killer cells, an effective amount of one or more genes selected from a group containing of lysozyme (BC002069), ferritin H chain (BC012314), brevican (X87096), matrix metalloproteinase 12 (BC019135), EIA-stimulated gene cellular inhibitor (AF084524), S100 calcium binding protein A9 (BC027635), MPS1 protein (L20315), transglutaminase 2 (BC016492), serum and glucocorticoid regulated protein kinase (AF139639), RIKEN cDNA 5830413L19 (BC027496), interferon-induced protein (BC003804), milk fat globul membrane protein EGF factor 8 (BC018577), cell-surface glycoprotein p91 (U83172), arginase 1 (BC050005), tumor necrosis factor receptor 1 (M59378), retinoid-induced serine carboxypeptidase (AF330052), FLJ11000 homologue (BC023802), interleukin-18 binding protein d precursor (AF110803), chloride channel 7 (AK009435), CD36 antigen (BC010262), zink finger protein homologue (BC030186), carbohydrate binding protein 35 (J03723), C-type calcium dependent carbohydrate (BC003218), lipoprotein lipase (NM\_008509), v-maf lacertus fibrosarcoma oncogene (BC038256), interleukin 7 receptor (NM\_008372), chemokine (C-C) receptor 1 (BC011092) and neurophilline (MGDIMG1:106206).

## Claim 30 (Previously Presented)

A method of treating a cancer comprising administering to a patient in need of such treatment or prevention, an effective amount of one or more genes selected from a group containing of lysozyme (BC002069), ferritin H chain (BC012314), brevican (X87096), matrix metalloproteinase 12 (BC019135), EIA-stimulated gene cellular inhibitor (AF084524), S100 calcium binding protein A9 (BC027635), MPS1 protein (L20315), transglutaminase 2 (BC016492), serum and glucocorticoid regulated protein kinase (AF139639), RIKEN cDNA 5830413L19 (BC027496), interferon-induced protein (BC003804), milk fat globul membrane protein EGF factor 8 (BC018577), cell-surface glycoprotein p91 (U83172), arginase 1 (BC050005), tumor necrosis factor receptor 1 (M59378), retinoid-induced serine carboxypeptidase (AF330052), FLJ11000 homologue (BC023802), interleukin-18 binding protein d precursor (AF110803), chloride channel 7 (AK009435), CD36 antigen (BC010262), zink finger protein homologue (BC030186), carbohydrate binding protein 35 (J03723), C-type calcium dependent carbohydrate (BC003218), lipoprotein lipase (NM\_008509), v-maf lacertus fibrosarcoma oncogene (BC038256), interleukin 7 receptor (NM\_008372), chemokine (C-C) receptor 1 (BC011092) and neurophilline (MGDIMG1:106206).

## Claim 31 (Previously Presented)

The method as set forth in claim 30, wherein the cancer is selected from a group consisting of breast cancer, melanoma and lung cancer.

## Claim 32-34 (Canceled)

Claim 35 (New)

The method as set forth in claim 29, wherein the gene is ferritin H chain  
(BC012314).

Claim 36 (New)

The method as set forth in claim 30, wherein the gene is ferritin H chain  
(BC012314).